Your browser doesn't support javascript.
loading
Application of ATP-tumor chemosensitivity assay in primary epithelial ovarian cancer / 中华肿瘤杂志
Chinese Journal of Oncology ; (12): 368-372, 2010.
Article in Chinese | WPRIM | ID: wpr-260397
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the predictive value of the adenosine triphosphate-tumor chemosensitivity assay (ATP-TCA) in the chemotherapy applied in primary epithelial ovarian cancer (PEOC), and to analyze if the neoadjuvant chemotherapy have any influence on the postoperative chemosensitivity.</p><p><b>METHODS</b>ATP-TCA results from 61 PEOC specimens were analyzed retrospectively. Patients were divided into sensitive group and resistant group according to the ATP-TCA results. Sensitive index (SI) was applied to analyze the ATP-TCA results. The correlation between in vitro results and clinical outcome was assessed by univariate and multivariate analysis.</p><p><b>RESULTS</b>SI set at > 250 had the highest test sensitivity, specificity, positive and negative predictive value of 91.6%, 73.9%, 84.6% and 85.0%, respectively. The ATP-TCA results had significant correlation with clinical outcome (chi(2) = 26.9, P < 0.001). Patients with tumors shown to be resistant had a higher risk of recurrence in comparison with those who were tested as sensitive (P = 0.030, OR = 0.033, 95%CI 0.002 approximately 0.724). The median progression-free survival (PFS) and overall survival (OS) of in vitro-sensitive patients were 26 months and 39 months, respectively, significantly longer than those in the in vitro drug-resistant group of patients (PFS 10 months and OS 25 months) (both P < 0.01). Neoadjuvant chemotherapy had a significant correlation with the clinical chemoresistance (chi(2) = 15.214, P < 0.001).</p><p><b>CONCLUSION</b>ATP-TCA assay may effectively predict the chemosensitivity of primary ovarian cancer, and predict the early recurrence of the tumor.</p>
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Ovarian Neoplasms / Carcinoma, Transitional Cell / Antineoplastic Combined Chemotherapy Protocols / Doxorubicin / Survival Rate / Retrospective Studies / Carboplatin / Cisplatin / Paclitaxel / Cystadenocarcinoma, Serous Type of study: Observational study / Prognostic study Limits: Female / Humans Language: Chinese Journal: Chinese Journal of Oncology Year: 2010 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Ovarian Neoplasms / Carcinoma, Transitional Cell / Antineoplastic Combined Chemotherapy Protocols / Doxorubicin / Survival Rate / Retrospective Studies / Carboplatin / Cisplatin / Paclitaxel / Cystadenocarcinoma, Serous Type of study: Observational study / Prognostic study Limits: Female / Humans Language: Chinese Journal: Chinese Journal of Oncology Year: 2010 Type: Article